

Pyoderma Gangrenosum Associated with Multiple Myeloma: a Paraneoplastic Syndrome or Paradoxical Skin Reaction

Sevgi Akarsu

Dokuz Eylul University, Faculty of Medicine, Department of Dermatology and Venereology, İzmir, Turkey.

***Corresponding Author:** Sevgi Akarsu, Professor, Dokuz Eylul University, Faculty of Medicine, Department of Dermatology and Venereology, İzmir, Turkey.

Received Date: October 07, 2024; **Accepted Date:** October 24, 2024; **Published Date:** November 14, 2024

Citation: Sevgi Akarsu, (2024), Pyoderma Gangrenosum Associated with Multiple Myeloma: a Paraneoplastic Syndrome or Paradoxical Skin Reaction, *Clinical Medical Reviews and Reports*, 6(9); DOI:10.31579/2690-8794/235

Copyright: © 2024, Sevgi Akarsu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The aim of this perspective article is to discuss the pathogenesis and treatment of pyoderma gangrenosum (PG), which can be seen as a paraneoplastic and/or drug-induced skin disorder in patients with multiple myeloma (MM). PG, a rare inflammatory neutrophilic dermatosis, may be idiopathic or associated with hematological malignancies at a rate of 3.9-45.6%. Among hematological malignancies, plasma cell dyscrasias (mostly IgA gammopathy) such as monoclonal gammopathy of undetermined significance and MM are the most frequently associated with PG. It is necessary to suspect and take place further investigations in terms of hematological malignancies including MM in cases of multifocal and recalcitrant ulcerative PG. Although conventional treatment in PG includes the use of immunosuppressive agents, PG may also occur in the presence of immunosuppression. Therefore, it should also be kept in mind that PG lesions may develop paradoxically when administering anti-myeloma treatments.

Keywords: pyoderma gangrenosum; multiple myeloma; paraneoplastic syndrome; paradoxical skin reaction

Introduction

One of the rare extramedullary manifestations of multiple myeloma (MM), a plasma cell dyscrasia, cutaneous involvement occurs in less than 1-2% of cases. Both the rarity of specific cutaneous involvement (plasmacytoma) and presence of mostly nonspecific dermatoses in MM pose a challenge for dermatologists to suspect MM in the presence of a skin lesion [1]. Therefore, a high degree of clinical doubt, detailed medical history and histopathological correlation are mandatory for early and accurate diagnosis and management [1-2]. The purpose of this perspective article is to discuss

the pathogenesis and treatment of MM-associated pyoderma gangrenosum (PG), which may be a paraneoplastic and/or a drug-induced dermatosis.

PG is an extremely rare (3-10 cases/million people/year) inflammatory, non-infectious neutrophilic dermatosis. It is characterized by painful necrotic ulcers that typically begin as an erythematous papulopustular lesion and rapidly enlarge with an irregular, violaceous and undermined borders, subsequently heal to leave permanent cribriform scars (Figure 1-2).



Figure 1. Rapidly progressing painful ulceration with necrotic areas and elevated erythematous-violaceous undermined edges




Figure 2. a) Erythematous papulopustular lesions, a round ulceration with violaceous and raised borders; **b)** subsequent healing with cribriform scars

Since there is no single pathognomonic finding, the diagnosis of PG is difficult and it can be confused with many conditions of circulatory, malignant or infectious origin. It is a diagnosis of exclusion with clinical presentation, compatible histopathology, negative cultures, positive pathergy, and even response to immunosuppressive treatment [2]. Diagnostic criteria for classic ulcerative PG were recently reported by the Delphi consensus of international experts [3].

Pyoderma gangrenosum as a paraneoplastic skin manifestation in multiple myeloma: PG, which can also be idiopathic, occurs in more than half of the cases in association with other conditions (inflammatory bowel disease, rheumatic disorders, hematological malignancies, respectively). The frequency of hematological malignancies associated with PG ranges from 3.9% to 45.6% [4-6]. In a systematic review examining 26 different diagnosis in 340 cases with PG-related hematological malignancies, myelodysplastic syndrome was observed most frequently, followed by monoclonal gammopathy of undetermined significance (MGUS), acute myeloid leukemia and MM. Of these cases, 22% were MGUS and 6.5% were MM, most of whom were IgA-type plasma cell dyscrasias [5]. When reviewing the literature, PG in some patients with plasma cell dyscrasia has been diagnosed before or concurrently with these hematological disorders [7-9]. In a recent population-based retrospective cohort study, it was shown that a previous history of hematological malignancy increased the likelihood of developing PG by approximately eight times. This association was reported most strongly for acute leukemia, MM, chronic leukemia, and non-Hodgkin's lymphoma. The highest rates of PG were observed in the first year following the diagnosis of hematological malignancy and gradually decreased thereafter. In this study, the risk of subsequent hematologic malignancy following PG diagnosis was not statistically higher than in the control group [6].

MM-associated PG is most commonly seen in the ulcerative type, shows a multifocal distribution, and has been found to be related with IgA kappa-type monoclonal gammopathy [5,10-12]. It has been demonstrated that bone marrow stromal cells secrete significantly higher levels of IL-8, and subsequent NF- κ B activation increase the survival of MM cells [8,13]. Moreover, IgA may play a role in the pathogenesis of PG by increasing NF- κ B activity, IL-8 production and neutrophil recruitment [14]. The significance of the predominance of IgA monoclonal gammopathy in patients with PG is unclear. Although the mechanism of this relationship is not fully understood, IgA paraprotein may contribute to the pathogenesis of PG and impaired skin healing by blocking the surface receptors of neutrophils or monocytes, reducing neutrophil chemotaxis and delaying leukocyte migration [10].

As known, PG treatment can be challenging. The mainstay of treatment is usually long-term immunosuppression, but it is widely stated that control of underlying diseases can lead to improvement of PG [2]. In these cases, surgery should be avoided because of the pathergy phenomenon or the development of new PG lesions (25-50%) even in minor trauma areas such as surgical incisions and venipuncture [15-16]. There is no specific treatment option for direct PG, and the aim is to control inflammation, reduce pain and accelerate healing. For this purpose, in addition to local wound care and treatments, oral dapsone, colchicine, systemic corticosteroids, cyclosporine, various immunosuppressive/immunomodulatory agents (e.g. methotrexate, thalidomide) and biologics (e.g. tumor necrosis factor- α inhibitors) are recommended depending on the severity of the lesions and the comorbid conditions of the patient [2]. It has been found that some MM-related PG cases were resistant to steroids, various immunosuppressive agents, apremilast, rituximab, IVIG and other biological treatments despite variable responses, and responded to oral proteasome inhibitors (often bortezomib, alternatively the new agent ixazomib) [11,17].

Pyoderma gangrenosum associated with anti-myeloma treatments: Although PG is generally classified as a paraneoplastic skin finding in patients with MM, it may also occur in association with some anti-myeloma agents [4,18-19]. While the conventional treatment of PG includes the use of immunosuppressive agents, interestingly, it has been observed that PG can develop in the presence of immunosuppression. In the literature, PG development has been reported in cases where immunosuppressive treatments were used after solid organ and allogeneic stem cell transplantations [20-24]. Additionally, there are conflicting results regarding the efficacy of thalidomide and its derivatives (immunomodulatory agents used in MM) in PG (25-29). Although the usefulness of thalidomide has been reported in some articles [25-26,29], cases with newly developed or recurrent PG lesions with lenalidomide have also been reported [8,26]. Interestingly, lenalidomide-induced PG lesions were observed to regress with pomalidomide, which belongs to the same pharmaceutical class [7]. Besides that, although TNF- α inhibitors and rituximab are recommended in the treatment of PG, paradoxical PG has also been observed in patients using these biological agents for other reasons [19]. There are also conflicting reports regarding the effect of TNF- α inhibitors on MM [30-31]. It has been found that TNF- α -neutralizing antibodies or infliximab increase the cytotoxic effect of anticancer drugs by suppressing the TNF receptor/mTOR/NF- κ B pathways [31]. However, progression to MM was observed with the use of infliximab in a patient with coexistence of PG and MGUS [30].

In routine practice, treatment is not recommended in asymptomatic silent plasma cell dyscrasias such as MGUS and smoldering MM, unless there is a progression to symptomatic MM. However, it has been observed that PG

accompanying such asymptomatic plasma cell dyscrasias is resistant to dermatological managements and responds to early anti-myeloma treatments (bortezomib+dexamethasone±cyclophosphamide) [32]. Indeed, satisfactory results have been obtained by performing MM treatments in patients with monoclonal gammopathy who are recalcitrant and progress with diffuse and aggressive PG lesions [33].

Conclusion

As we know, it is necessary to suspect and take place further investigations in terms of hematological malignancies including MM in cases of multifocal immunosuppressive/immunomodulatory and biological agents also have conflicting effects on PG and MM. Therefore, it should also be kept in mind that PG lesions may develop paradoxically when administering anti-myeloma treatments.

References:

1. Woo YR, Kim JS, Lim JH, Hwang S, Kim M,et.al (2018). Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: A case series from Korea. *J Am Acad Dermatol* ;78:471-478.e4.
2. Maronese CA, Pimentel MA, Li MM, Genovese G, Ortega-Loayza AG,et.al (2022). Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. *Am J Clin Dermatol* ;23:615-634.
3. Maverakis E, Ma C, Shinkai K, Fiorentino D, Callen JP,et.al (2018). Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi Consensus of International Experts. *JAMA Dermatol* ;154:461-466.
4. Gupta AS, Ortega-Loayza AG (2019). Pyoderma gangrenosum: a too often overlooked facultative paraneoplastic disease. *Ann Hematol* ;98:2247-2248.
5. Montagnon CM, Fracica EA, Patel AA, Camilleri MJ, Murad MH,et.al (2020). Pyoderma gangrenosum in hematologic malignancies: A systematic review. *J Am Acad Dermatol* 82:1346-1359.
6. Kridin K, Ankary-Khaner M, Kridin M, Cohen AD, Badarny S (2024). Hematological malignancy-associated pyoderma gangrenosum: evaluating the magnitude of the association. *Front Med (Lausanne)* ; 11: 1425454.
7. Meunier M, Larabi A, Schacherer M, Deteix C, Courby S, Cahn JY (2020). Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma. *Ann Hematol* ;99:379-380.
8. Razmi T M, Muhammed H, Handa S, Malhotra P, Sharma S, Saikia UN,et.al (2019). Bullous pyoderma gangrenosum secondary to underlying multiple myeloma: treated with ciclosporin. *Clin Exp Dermatol* ;44:e13-e15.
9. Ahmad K, Ramsay B (2009). Pyoderma gangrenosum associated with subcorneal pustular dermatosis and IgA myeloma. *Clin Exp Dermatol* ;34:46-48.
10. Yoon YH, Cho WI, Seo SJ (2006). Case of multiple myeloma associated with extramedullary cutaneous plasmacytoma and pyoderma gangrenosum. *Int J Dermatol* ;45:594-597.
11. Kikuchi Y, Yoshimi M, Takahashi T (2016). Pyoderma gangrenosum in a patient with multiple myeloma. *Intern Med* ;55:711.
12. de la Iglesia Martin J, Alegre M, Mascaró Galy JM (2024). Pyoderma gangrenosum and IgA Myeloma. *Med Clin (Barc)* : S0025-7753(24)00301-4.
13. Markovina S, Callander NS, O'Connor SL, Xu G, Shi Y,et.al (2010). Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. *Mol Cancer* ;9:176.
14. Duque N, Gómez-Guerrero C, Egido J (1997). Interaction of IgA with Fc alpha receptors of human mesangial cells activates transcription factor nuclear factor-kappa B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. *J Immunol* 1997;159:3474-3482.
15. Lamet S, Bracke A, Geluykens E, Vlieghe E, Seymons K(2010). Medical and surgical management of paraneoplastic pyoderma gangrenosum--a case report and review of the literature. *Acta Clin Belg* 2010;65:37-40.
16. Lyu J, Wang S, Zhang H, Liu S (2022). Acupuncture-exacerbated pyoderma gangrenosum associated with IgG multiple myeloma. *Wounds* ; 34(11): E108-E111.
17. Cespedes DA, Gallitano SM, Bhutani D (2022). Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma. *Ann Hematol* 2022;101:441-442.
18. Wang JY, French LE, Shear NH, Amiri A, Alavi A (2018). Drug-induced pyoderma gangrenosum: a review. *Am J Clin Dermatol* ;19:67-77.
19. Lytvyn Y, Mufti A, Maliyar K, Sachdeva M, Yeung J (2022). Onset of pyoderma gangrenosum in patients on biologic therapies: a systematic review. *Adv Skin Wound Care* ;35:454-460.
20. Bittencourt MCB, Atanazio MJ, Xavier EM, Costa SF (2018). Postsurgical pyoderma gangrenosum after an autologous stem cell transplantation for multiple myeloma. *BMJ Case Rep* ;bcr2017222286.
21. Blanc D, Schreiber M, Racadot E, Kahn JY, Flesch M,et.al (1989). Pyoderma gangrenosum in an allogeneic bone marrow transplant recipient. *Clin Exp Dermatol* ;14:376-379.
22. Elenberg Y, Shani-Adir A, Hecht Y, Ephros M, Bibi H (2010). Pyoderma gangrenosum after bone marrow transplantation for leukocyte adhesion deficiency type 1. *Isr Med Assoc J* ;12:119-120.
23. Jha PK, Rana A, Kapoor S, Kher V (2015). Pyoderma gangrenosum in a renal transplant recipient: A case report and review of literature. *Indian J Nephrol* ;25:297-299.
24. Haim S, Friedman-Birnbaum R (1976). Pyoderma gangrenosum in immunosuppressed patients. *Dermatologica* ;153:44-48.
25. Chen M, Doherty SD, Hsu S (2010). Innovative uses of thalidomide. *Dermatol Clin* ;28:577-586.
26. Federman GL, Federman DG (2000). Recalcitrant pyoderma gangrenosum treated with thalidomide. *Mayo Clin Proc* ;75:842-844.
27. Dasanu CA, Bockorny B, Alexandrescu DT (2015). Pyoderma gangrenosum due to lenalidomide use for multiple myeloma. *J Oncol Pharm Pract* ;21:471-473.
28. Holstein SA, McCarthy PL (2017). Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. *Drugs* ;77:505-520.
29. Verrou E, Kartsios C, Banti A, Mihou D, Kaloutsi V, et.al (2007). IgG multiple myeloma presented with ulcerative pyoderma gangrenosum. *Leuk Lymphoma* ;48:1420-1422.
30. Shareef MS, Munro LR, Owen RG, Highet AS (2012). Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum. *Clin Exp Dermatol* ;37:146-148.
31. Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K,et.al (2013). Inhibition of the tumour necrosis factor-alpha autocrine loop enhances the sensitivity of multiple myeloma cells to anticancer drugs. *Eur J Cancer* ;49:3708-3717.
32. Nahi H, Afram G, Brauner H, Talme T, Kuzmina N (2021). Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti-myeloma treatment. *Int J Dermatol* ;60:e271-e273.

33. Velasco-Tamariz V, Carreño-Tarragona G, Tous-Romero F, Gil-de la Cruz E, Martín-Clavero E, Rivera-Díaz R (2017). Dramatic resolution of disseminated pyoderma gangrenosum associated

with monoclonal gammopathy after therapy with bortezomib and dexamethasone. *Int Wound J* ;14:1382-1384.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

Submit Manuscript

DOI:10.31579/2690-8794/235

Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more <https://auctoresonline.org/journals/clinical-medical-reviews-and-reports>